帕金森病患者微生物酪氨酸脱羧酶基因与左旋多巴反应性的关联
这项横断面研究纳入101例帕金森病患者并另设43例外部队列,用左旋多巴冲击试验评估反应性,发现反应中等者粪便tyrDC基因和粪肠球菌丰度高于反应良好者,tyrDC基因丰度与左旋多巴反应性独立相关,并具有一定区分能力。
要点
- 反应中等者tyrDC基因丰度3.6(3.1-4.3)高于反应良好者2.6(2.1-2.9),p<0.001。
- 反应中等者粪肠球菌丰度3.2(2.5-4.4)高于反应良好者2.6(2.1-3.6),p=0.010。
- tyrDC基因丰度与左旋多巴反应性独立相关,OR为5.848(95%CI 2.664-12.838),p<0.001。
核心结论
- 微生物tyrDC基因丰度可作为左旋多巴反应性的潜在生物标志物,靶向tyrDC基因的新策略可能为个性化左旋多巴治疗提供新途径。
研究设计与样本
- 横断面研究,于2019年12月至2022年1月纳入帕金森病患者,用左旋多巴冲击试验评估反应性并分为反应中等和反应良好两组,用实时荧光定量PCR测粪便tyrDC基因和粪肠球菌丰度,用液相色谱-串联质谱测血浆左旋多巴浓度。
- 主要队列纳入101例帕金森病患者,外部验证队列纳入43例。
主要发现
- 反应中等者tyrDC基因丰度为3.6(3.1-4.3),高于反应良好者的2.6(2.1-2.9),p<0.001。
- 反应中等者粪肠球菌丰度为3.2(2.5-4.4),高于反应良好者的2.6(2.1-3.6),p=0.010。
- tyrDC基因丰度与左旋多巴反应性独立相关,OR为5.848(95%CI 2.664-12.838),p<0.001。
- 主要队列中tyrDC基因丰度区分左旋多巴反应性的敏感度80.0%、特异度84.3%、AUC 0.85(95%CI 0.77-0.93),p<0.001。
- 外部验证队列中敏感度85.0%、特异度95.7%、AUC 0.95(95%CI 0.89-1.02),p<0.001。
关键数值与推荐
- 基于tyrDC基因丰度的预测模型交叉验证中训练集和测试集C-index分别为0.856和0.851,外部验证C-index为0.952。
临床怎么用
- 作者认为微生物tyrDC基因丰度可作为左旋多巴反应性的潜在生物标志物,靶向tyrDC基因的新策略可能为个性化左旋多巴治疗提供新途径。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Interindividual variability in levodopa efficacy is a challenge for the personalized treatment of Parkinson disease (PD). Gut microbiota might represent a new approach for personalized medicine. Recently, a novel microbial levodopa metabolism pathway was identified, which is mediated by tyrosine decarboxylase mainly encoded by tyrosine decarboxylase gene (tyrDC) in Enterococcus faecalis. In this study, we aimed to identify whether the abundance of microbial tyrDC gene and E faecalis is associated with levodopa responsiveness and could predict the drug response. METHODS: This cross-sectional study enrolled patients with PD between December 2019 and January 2022 and evaluated levodopa responsiveness using a levodopa challenge test. Patients were stratified into moderate and good responders based on levodopa responsiveness. The tyrDC gene and E. faecalis abundance in fecal samples were measured using quantitative real-time PCR. Plasma levodopa concentrations were measured using liquid chromatography-tandem mass spectrometry analysis. The predictive models for levodopa responsiveness were constructed and verified through cross-validation and external validation. RESULTS: A total of 101 patients with PD were enrolled in the primary cohort and 43 were enrolled in the external validation cohort. Moderate responders had higher abundances of the tyrDC gene (3.6 [3.1-4.3] vs 2.6 [2.1-2.9], p < 0.001) and E faecalis (3.2 [2.5-4.4] vs 2.6 [2.1-3.6], p = 0.010) than good responders. The tyrDC gene abundance was independently associated with levodopa responsiveness (OR: 5.848; 95% CI: 2.664-12.838; p < 0.001). Notably, tyrDC gene abundance showed certain discriminative power for levodopa responsiveness in primary cohort (sensitivity: 80.0%; specificity: 84.3%; area under the curve [AUC]: 0.85; 95% CI: 0.77-0.93; p < 0.001) and external validation cohort (sensitivity: 85.0%; specificity: 95.7%; AUC: 0.95; 95% CI: 0.89-1.02; p < 0.001). The prediction of levodopa responsiveness based on tyrDC gene abundance had good calibration and discrimination in cross-validation (C-index in training and test sets: 0.856 and 0.851, respectively) and external validation (C-index: 0.952). DISCUSSION: The microbial tyrDC gene abundance could serve as a potential biomarker of levodopa responsiveness. Novel strategies targeting the tyrDC gene may provide new approaches for personalized levodopa treatment.
引用
- Zhang Y, He X, Mo C, et al. Association Between Microbial Tyrosine Decarboxylase Gene and Levodopa Responsiveness in Patients With Parkinson Disease. Neurology. 2022. PMID: 36240098. doi:10.1212/WNL.0000000000201204
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。